Cargando…
The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan
BACKGROUND: Since June 2019, cancer genomic profiling (CGP) tests have been reimbursed by the National Health Insurance system in Japan, with restrictions for government-designated hospitals with a molecular tumor board composed of multidisciplinary specialists, known as an expert panel (EP). The st...
Autores principales: | Sunami, Kuniko, Naito, Yoichi, Aimono, Eriko, Amano, Toraji, Ennishi, Daisuke, Kage, Hidenori, Kanai, Masashi, Komine, Keigo, Koyama, Takafumi, Maeda, Takahiro, Morita, Sachi, Sakai, Daisuke, Kohsaka, Shinji, Tsuchihara, Katsuya, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895780/ https://www.ncbi.nlm.nih.gov/pubmed/33385275 http://dx.doi.org/10.1007/s10147-020-01844-1 |
Ejemplares similares
-
Chronological improvement in precision oncology implementation in Japan
por: Sunami, Kuniko, et al.
Publicado: (2022) -
Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors
por: Imai, Mitsuho, et al.
Publicado: (2022) -
Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan
por: Naito, Yoichi, et al.
Publicado: (2022) -
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
por: Sunami, Kuniko, et al.
Publicado: (2023) -
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA
por: Sunami, Kuniko, et al.
Publicado: (2021)